Promising research using a PARP inhibitor to treat metastatic breast cancer in people with an inherited PALB2 mutation or a tumor mutation in BRCA1 or BRCA2
Full article: https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.1002
Early results of a small study showed that women with metastatic breast cancer and an inherited mutation in PALB2 or an acquired tumor mutation in BRCA1 or BRCA2 benefitted from the PARP inhibitor olaparib (Lynparza). (6/18/20)
Questions To Ask Your Health Care Provider
- I have metastatic breast cancer and a BRCA mutation; should I consider treatment with a PARP inhibitor?
- What are the risks and benefits of treatment with a PARP inhibitor?
- I have a personal or family history of cancer, but I have not had genetic testing; should I consider having genetic testing?
- I have metastatic breast cancer and an inherited mutation in a gene that is not BRCA1 or BRCA2; are there any therapies or clinical trials that I should consider?
- Should I have tumor biomarker testing to see which treatment would be most useful for treating my metastatic breast cancer?
- As a person with an inherited mutation in a DNA damage response gene, what other cancer risks should I be aware of?
Open Clinical Trials
The following are studies looking at PARP inhibitors as treatment for advanced breast cancer:
- NCT05169437: PARP inhibitor (niraparib) in patients with inherited or tumor PALB2 mutations in advanced solid tumors (PAVO). PAVO is a Phase II study investigating if the study drug, a PARP inhibitor called niraparib, is safe and effective for certain people who have been diagnosed with an advanced solid tumor with either an inherited or tumor PALB2 mutation.
- NCT03344965: Olaparib Expanded - Treating Metastatic Breast Cancer in People without gBRCA Mutations. This study is looking at whether olaparib is also effective for treating metastatic breast cancer in people who do not have an inherited BRCA mutation. The study is enrolling people with an inherited mutation in PALB2 or an acquired (tumor) mutation in BRCA1 or BRCA2.
- NCT04039230: Study to Evaluate Sacituzumab Govitecan in Combination With Talazoparib in Patients With Metastatic Breast Cancer. This studies the effect of Antibody-Drug Conjugate Sacituzumab Govitecan in Combination with the PARP Inhibitor Talazoparib in Patients with Metastatic TNBC.
- NCT03990896: Talazoparib for People with Metastatic Breast Cancer Who Have Acquired (Somatic) BRCA Mutations. This is a study for patients with metastatic breast cancer without a known mutation in BRCA1 or BRCA2, who learn they have a BRCA1 or BRCA2 acquired (tumor) mutation, found through liquid biopsy.
- NCT04550494: Treating Metastatic Solid Tumors with an Inherited or Acquired Gene Mutation Using the PARP Inhibitor Talazoparib. This study is looking whether the drug talazoparib (also known as Talzenna) is safe and effective for treating people with advanced breast, gastric, ovarian, pancreatic, or other solid tumors with an inherited mutation or an acquired mutation in certain DNA repair genes, such as BRCA1, BRCA2, ATM, CHEK2, PALB2 and others.
- NCT05252390: NUV-868 Alone and in Combination With PARP Inhibitors in Patients With Advanced Solid Tumors. This study will test how safe and effective the experimental drug NUV-868 is by itself and in combination with a PARP inhibitor in people with advanced solid tumors.
A number of other clinical trials for treating patients with metastatic breast cancer can be found here.
The following studies are looking at treatment for people with advanced solid tumors.
- NCT05252390: NUV-868 Alone and in Combination With PARP Inhibitors in Patients With Advanced Solid Tumors.This study will test the safety and effectiveness of the experimental drug NUV-868 alone and combined with a PARP inhibitor in people with advanced solid tumors. This study is open to people whose cancer stopped responding or progressed on PARP inhibitors.
- NCT05169437: PARP inhibitor (niraparib) in patients with inherited or tumor PALB2 mutations in advanced solid tumors (PAVO). PAVO is a Phase II study investigating if the PARP inhibitor niraparib is safe and effective for people with an advanced solid tumor who have an inherited PALB2 gene mutation or a tumor with a PALB2 mutation.
- NCT02264678: Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents. This is a study of ceralasertib administered orally in combination with chemotherapy regimens and/or novel anticancer agents to patients with advanced cancer. The study is enrolling people with inherited mutations, including BRCA1, BRCA2, ATM, RAD51C, RAD51D, and people with tumors that are HRD-positive.
- NCT04644068: Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies (PETRA). This research is designed to learn whether treatment with a new PARP inhibitor, AZD5305, used alone or in combination with anti-cancer agents is safe, tolerable and has anti-cancer activity in patients with advanced solid tumors. The study is open to people who have previously been treated with PARP inhibitors.
- NCT04267939: ATR Inhibitor Plus Niraparib Study in Advanced Solid Tumors and Ovarian Cancer. This study will look at how well people with advanced solid tumors respond to treatment with the targeted therapy BAY1895344 in combination with the PARP inhibitor niraparib. This study is open to people with inherited mutations in ATM, BRCA1, BRCA2 and other genes. Contact the study coordinator for information about eligibility for people with mutations in other genes.
- NCT04657068: Treatment with ATR Inhibitor for Advanced or Metastatic Solid Tumors. This study will look at how well a new oral targeted therapy known as an ATR inhibitor works on advanced or metastatic solid tumors with mutations in genes that are linked to DNA damage repair. This study is open to people who have an inherited or acquired BRCA or ATM mutation or whose tumors are HRD-positive. This study is open to people whose cancer stopped responding or progressed on PARP inhibitors.
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.